Genocea Biosciences Inc GNCAQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- — / —
- Market Cap
- $58.78
- Volume/Avg
- 4,500 / 7,620
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 74
- Website
- https://www.genocea.com
Valuation
|
Metric
|
GNCAQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GNCAQ
|
|---|---|
Quick Ratio | 1.12 |
Current Ratio | 1.35 |
Interest Coverage | −33.66 |
Quick Ratio
GNCAQ
Profitability
|
Metric
|
GNCAQ
|
|---|---|
Return on Assets (Normalized) | −81.83% |
Return on Equity (Normalized) | −316.05% |
Return on Invested Capital (Normalized) | −148.28% |
Return on Assets
GNCAQ
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dhnfpptd | Gwlzf | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Npxcmgt | Qzglzc | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zykbgpxg | Qdrtf | $107.6 Bil | |
MRNA
| Moderna Inc | Zsptstdrr | Zdzpj | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Zznhqdfln | Zgc | $22.2 Bil | |
ARGX
| argenx SE ADR | Zxyvmlfk | Csssv | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wdtgswwr | Sgysjc | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ydgmvsjfq | Qqqtnbr | $15.1 Bil | |
INCY
| Incyte Corp | Tgpqvyfq | Kshglp | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yrcyzbnbh | Mlsqlmc | $12.7 Bil |